The Wholly-owned Subsidiary Of Shenzhen Hybio Pharmaceutical Co., Ltd. Has Obtained The Approval Notice For Marketing Application For Cetrorelix API.

Feb 06, 2026

Leave a message

On July 11, 2023, Hybio Pharmaceutical (Wuhan) Co., Ltd. (hereinafter referred to as "Hybio Wuhan"), a wholly-owned subsidiary of Shenzhen Hybio Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company" or "Hybio Pharmaceutical"), received the Approval Notice for Marketing Application of Chemical Active Pharmaceutical Ingredient (Acceptance No.: CYHS2260223) issued by the National Medical Products Administration (NMPA) for its Cetrorelix Acetate API, and the relevant information has been publicized on the official website of the Center for Drug Evaluation (CDE) under the NMPA. We hereby announce the relevant details as follows:

I. Registration Information of the API

Generic Name: Cetrorelix Acetate

Registration No.: Y20220000234

Packaging Specifications: 1g/bag; 2g/bag; 5g/bag; 10g/bag; 15g/bag; 20g/bag; 50g/bag

Manufacturer: Hybio Pharmaceutical (Wuhan) Co., Ltd.

Application Item: Marketing application for domestically manufactured chemical API and joint review with its finished dosage forms

Result: A (Approved for use in marketed finished dosage forms)

II. Other Information about the Drug

Cetrorelix Acetate is a synthetic decapeptide, whose finished dosage form is an injectable gonadotropin-releasing hormone (GnRH) antagonist, indicated for assisted reproduction and the inhibition of premature luteinizing hormone (LH) surge.

Send Inquiry
Contact usif have any question

You can either contact us via phone, email or online form below. Our specialist will contact you back shortly.

Contact now!